Hyperprogression of brain metastases following initiation of immune checkpoint inhibitors - Takeaways - MDSpire

Hyperprogression of brain metastases following initiation of immune checkpoint inhibitors

  • By

  • Charissa A. C. Jessurun

  • Francesca Siddi

  • Noah L.A. Nawabi

  • Alexander F. C. Hulsbergen

  • Yu Tung Lo

  • Rohan Jha

  • Timothy R. Smith

  • Marike L. D. Broekman

  • February 7, 2025

  • 0 min

Share

  • 1

    Immune checkpoint inhibitors (ICI) have shown varying efficacy in treating brain metastases, with response rates differing by cancer type.

  • 2

    Hyperprogressive disease (HPD) can occur in a subset of patients after ICI initiation, characterized by rapid tumor growth and poor prognosis.

  • 3

    In a study of 25 patients, 20% experienced HPD, with tumor growth rates increasing significantly post-ICI treatment.

  • 4

    The median overall survival for patients developing HPD is approximately 3 months, highlighting the severity of this condition.

  • 5

    Understanding HPD's development in brain metastases is crucial due to its potential for rapid neurological deterioration.

Original Source(s)

Hyperprogression of brain metastases following initiation of immune checkpoint inhibitors

  • by Charissa A. C. Jessurun, Francesca Siddi, Noah L.A. Nawabi, Alexander F. C. Hulsbergen, Yu Tung Lo, Rohan Jha, Timothy R. Smith, Marike L. D. Broekman

  • February 7, 2025

Related Content

Case report: complete pathologic response to neoadjuvant ensartinib in locally advanced, ALK-positive lung squamous cell carcinoma

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

HHLA2 as an emerging immune checkpoint in lung cancer: linking EGFR signaling, macrophage polarization, and CD8+ T-cell metabolic suppression